Failed B cell survival factor trials support the importance of memory B cells in multiple sclerosis-Reference-Cited by-同舟云学术

Failed B cell survival factor trials support the importance of memory B cells in multiple sclerosis

Published:2019-11-06 Issue:2 Volume:27 Page:221-228
ISSN:1351-5101
Container-title:European Journal of Neurology
language:en
Short-container-title:Eur J Neurol

Author:

Baker D.¹^ORCID,Pryce G.¹,James L. K.¹,Schmierer K.¹²^ORCID,Giovannoni G.¹²

Affiliation:

1. Blizard Institute Queen Mary University of London LondonUK

2. Clinical Board: Medicine [Neuroscience] Barts Health NHS Trust London UK

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ene.14105

Reference31 articles.

1. Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis

2. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

3. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial

4. ATON: Results from a Phase II randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritis

5. Efficacy and safety of tabalumab in patients with relapsing–remitting multiple sclerosis: a randomized, double‐blind, placebo‐controlled study;Silk M;Neurology,2018

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Memory B cell–guided extended interval dosing of ocrelizumab in multiple sclerosis;Multiple Sclerosis Journal;2024-05-20

2. Targeting Epstein–Barr virus in multiple sclerosis: when and how?;Current Opinion in Neurology;2024-03-21

3. Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability;Drugs;2024-03

4. B cell activating factor levels are linked to distinct B cell markers in multiple sclerosis and following B cell depletion and repopulation;Clinical Immunology;2024-01

5. Cladribine and ocrelizumab induce differential miRNA profiles in peripheral blood mononucleated cells from relapsing–remitting multiple sclerosis patients;Frontiers in Immunology;2023-12-13